Open Trial of Escitalopram Treatment for Male Subjects With Posttraumatic Stress Disorder

• Status: Completed
• Trial end date: 2004-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

The primary aim of this pilot study is to test the efficacy of the selective serotonin re-uptake inhibitor, Escitalopram, in the treatment of posttraumatic stress disorder (PTSD) in an open clinical trial.

A secondary aim is to determine whether treatment with escitalopram increases plasma allopregnanolone levels in patients with PTSD and if increases in allopregnanolone levels are correlated with treatment efficacy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Northern California Institute of Research and Education
• Treatments: Citalopram; Dexetimide

Criteria

Inclusion Criteria:

• Current DSM-IV TR PTSD and a score > 40 on the CAPS, as a result of a traumatic event that occurred at least 6 months prior to evaluation.

Exclusion Criteria:

• Lifetime history of bipolar or any psychiatric disorder with psychotic features.

• Prominent suicidal or homicidal ideation.

• History of alcohol abuse/dependence within the past 3 months.

• History of drug abuse/dependence within the past 6 months.

• Subjects who plan to start a new form of psychotherapy during the protocol.

• History of sleep apnea, neurological disorder and/or current systemic illness affecting central nervous system function.

• History of myocardial infarction in the past year.

• Subjects on antipsychotic medications, systemic steroid medication, antidepressants, mood stabilizers, antianxiety medication, or benzodiazepines within the past 2 weeks.

• Use of Citalopram or Escitalopram within the past 6 months.